The analysis of serum VEGF in the ovarian cancer patient group with no residual tumor after surgery (TR 0) and remaining tumor (TR >1 cm or TR <1 cm) revealed that both the group with residual tumor <1 cm and the group with residual tumor >1 cm had significant higher values of serum VEGF at day 0 in comparison to the group with no remaining tumor (p = 0,049 and p = 0,003, respectively) (Fig. 2b). The gene discussed is VEGFA; the disease is ovarian carcinoma.